Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment

Table 2 Pre-study dopamine agonist, allocated treatment arm, first and second IMP and daily dose and duration of IMP treatments

Patient study code	Pre-study dopamine agonist	Trial arm	First IMP	Daily dose (mg)	Number of days on IMP	Second IMP	Daily dose (mg)	Number of days on IMP
PD1	RPR	1	PPX	2.1	3	RPR^{a, b}	8	134
PD2	RPR	1	PPX	2.62	58	RPR	10	48
PD3	RPR	2	RPR	6	51	PPX	1.57	58
PD4	RPR	2	RPR	4	40	PPX	1.05	55
PD5	Consented but then withdrew before taking first IMP
PD6	PPX	1	PPX	2.1	64	RPR	8	52
PD7	PPX	2	RPR	10	13	PPX^{a, b}	2.62	97
PD8	RPR	2	RPR	12	54	PPX	3.15	62
PD9	PPX	1	PPX	1.57	62	RPR	6	56
PD10	RPR	1	PPX	2.1	53	RPR	8	68
PD11	PPX	1	PPX	1.05	48	RPR^b	4	30
PD12	PPX	2	RPR	10	52	PPX	2.62	56
PD13	Consented but then withdrew before taking first IMP
PD14	PPX	1	PPX	0.52	52	RPR	2	37
PD15	Consented but then withdrew before taking first IMP
PD16	PPX	1	PPX	1.57	63	RPR	6	55
PD17	PPX	2	RPR	6	60	PPX	1.57	37
PD18	PPX	2	RPR	6	3	Withdrew from IMP and study
PD19	RPR	1	PPX	2.1	55	RPR	8	84
PD20	PPX	2	RPR	8	66	PPX	2.1	41
PD21	PPX	1	PPX	3.15	100	RPR^b	12	7
PD22	RPR	2	RPR	6	55	PPX	1.57	48
PD23	PPX	2	RPR	8	5	Withdrew from IMP and study
PD24	RPR	2	RPR	6	58	PPX	1.57	37
PD25	RPR	2	RPR	2	68	PPX	0.52	62

PPX pramipexole PR, RPR ropinirole
^aWithdrew from study and reverted to pre-study dopamine agonist
^bDiscontinued their assigned treatment due to non-serious adverse events, reverted back to pre-study agonist but agreed to remain in study to test study processes

ISSN: 2055-5784